A discussion on updates presented at the ASH (American Society of Hematology) 2020 Annual Meeting on developments in the management of relapsed/refractory B-cell lymphomas.

Data from the following clinical trials are discussed:

Abstract 339: Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Abstract 403: Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Abstract 2104: A Phase I Investigator Sponsored Trial of Selinexor (KPT-330) and Rituximab, Ifosfamide, Carboplatin and Etoposide in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas

Abstract 599: Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Abstract 598: Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Videos

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

Key opinion leaders provide insight into data updates from the ASH (American Society of Hematology) 2020 Annual Meeting on developments in agents for the management of non-CLL (chronic lymphocytic leukemia) B-cell lymphomas.

Abstract 2109: Selinexor in Combination with R-CHOP for Front-Line Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

Abstract 405: Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

Experts in the management of hematologic malignancies discuss various abstracts and data updates presented at the ASH (American Society of Hematology) 2020 Annual Meeting on chronic lymphocytic leukemia (CLL).

Abstract 123: Ibrutinib (Ibr) Plus Venetoclax (Ven) First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study 

Abstract 1318: Zanubrutinib in Combination with Venetoclax for Patients with Treatment Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p) Arm D of the SEQUOIA (BGB-3111-304) Trial

Abstract 125: Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Woyach Abstract 1305: Three-Year Follow-Up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Abstract 2216: Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Abstract 544: Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Abstract 545: Safety and Efficacy of CD19-CAR T Cells in Richter’s Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

Sarah Rutherford, MD, Weill Cornell Medical College

Articles

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

ASH 2020 Updates in CLL